<DOC>
	<DOCNO>NCT00860574</DOCNO>
	<brief_summary>This phase II trial study well give treosulfan together fludarabine phosphate total-body irradiation follow donor stem cell transplant work treat patient high-risk acute myeloid leukemia , myelodysplastic syndrome , acute lymphoblastic leukemia . Giving chemotherapy , treosulfan fludarabine phosphate , total-body irradiation donor bone marrow peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus methotrexate transplant may stop happen</brief_summary>
	<brief_title>Treosulfan , Fludarabine Phosphate , Total-Body Irradiation Before Donor Stem Cell Transplant Treating Patients With High-Risk Acute Myeloid Leukemia , Myelodysplastic Syndrome , Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Decrease incidence relapse &lt; 15 % 6 month post transplant patient high risk acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) transplant related unrelated donor , without unacceptably increase toxicity ( 10 % non-relapse mortality [ NRM ] 6 month ) . SECONDARY OBJECTIVES : I . Evaluate incidence NRM 180 day 1 year hematopoietic cell transplantation ( HCT ) . II . Evaluate overall survival ( OS ) relapse-free survival ( RFS ) . III . Incidence grade II-IV acute graft-versus-host disease ( GVHD ) . IV . Incidence chronic GVHD . V. Donor chimerism day +28 +100 . OUTLINE : CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -6 day -2 treosulfan IV 2 hour day -6 day -4 . Patients also undergo total-body irradiation day 0 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell transplantation bone marrow transplantation day 0 . GVHD PROPHYLAXIS : Patients receive tacrolimus IV continuously orally ( PO ) twice daily ( BID ) day -1 56 , follow taper day 180 absence GVHD . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<criteria>Acute myeloid leukemia ( AML ) : All AML patient beyond 1st remission ; Intermediate high risk AML patient ( base South West Oncology Group [ SWOG ] cytogenetic criterion ) 1st complete remission Myelodysplastic syndrome ( MDS ) Other myeloid malignancy chronic myelogenous leukemia ( CML ) , CML accelerate phase , CML blast crisis , chronic myelomonocytic leukemia ( CMML ) ( approve patient care conference [ PCC ] ) With Karnofsky Index Lansky PlayPerformance Scale &gt; 70 % pretransplant evaluation Able give inform consent ( &gt; 18 year ) , legal guardian capable give informed consent ( &lt; 18 year ) Previous autologous allogeneic HCT allow Donors must : Human leukocyte antigen ( HLA ) identical related donor Unrelated donor match HLAA , B , C , DRB1 , DQB1 define high resolution deoxyribonucleic acid ( DNA ) type mismatch one HLA allele , except HLAC mismatch allow Able undergo peripheral blood stem cell collection bone marrow harvest In good general health , Karnofsky Lansky Play Performance score &gt; 90 % Able give inform consent ( &gt; 18 year ) , legal guardian capable give informed consent ( &lt; 18 year ) Acute lymphoblastic leukemia ( ALL ) : ALL patient eligible protocol Receiving umbilical cord blood With impaired cardiac function evidence ejection fraction &lt; 35 % cardiac insufficiency require treatment symptomatic coronary artery disease With impaired pulmonary function evidence partial pressure oxygen ( pO2 ) &lt; 70 mm Hg diffusing capacity lung carbon monoxide ( DLCO ) &lt; 70 % predict pO2 &lt; 80 mm Hg DLCO &lt; 60 % predict ; receive supplementary continuous oxygen With impaired renal function evidence creatinineclearance &lt; 50 % age , weight , height serum creatinine &gt; 2x upper normal limit dialysisdependent With hepatic dysfunction evidence total bilirubin aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.0 x upper normal limit evidence synthetic dysfunction severe cirrhosis With active infectious disease require deferral conditioning , recommend Infectious Disease specialist With human immunodeficiency virus ( HIV ) positivity active infectious hepatitis possible risk lethal infection treat immunosuppressive therapy With central nervous system ( CNS ) leukemic involvement clear intrathecal chemotherapy and/or cranial radiation prior initiate conditioning ( day 6 ) With life expectancy severely limited disease malignancy Women pregnant lactate possible risk fetus infant With known hypersensitivity treosulfan and/or fludarabine Receiving another experimental drug within 4 week initiation conditioning ( day 6 ) Unable give inform consent ( &gt; 18 year ) legal guardian ( &lt; 18 year ) unable give inform consent Ineligible donor : Deemed unable undergo marrow harvest PBSC mobilization leukapheresis Who HIVpositive With active infectious hepatitis Females positive pregnancy test Unable give inform consent ( &gt; 18 year ) legal guardian ( &lt; 18 year ) unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>